FTSE MIB
34.181,93 +242,18 (+0,71%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,81 +0,24 (+0,29%) Bitcoin EUR
59.903,29 +497,25 (+0,84%)
electroCore, Inc. (ECOR)
| Chiusura precedente | 5,58 |
| Aperto | 5,58 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 5,43 - 5,83 |
| Intervallo di 52 settimane | 3,83 - 8,08 |
| Volume | |
| Media Volume | 10.096 |
| Capitalizzazione | 33,915M |
| Beta (5 anni mensile) | 0,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,42 |
| Prossima data utili | 01 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 23,10 |
GlobeNewswireelectroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a treatment protocol for nVNS. U.S. Patent No. 11,779,756 entitled “Systems and Methods for Vagal Nerve Stimulation” was issued on October 10, 2023, and is generally related to a preferable treatment paradigm for nVNS that involves applying a single dose of s
- GlobeNewswire
Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress
“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) “NOVIS” Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will complete recruitment in 2023 ROCKAWAY, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke
- GlobeNewswire
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, November 8, 2023, 4:30 PM ESTDomestic: 877-407-8835Inter
